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The present study reports the results of a combined computational and site mutagenesis study designed to provide new insights
into the orthosteric binding site of the human M3 muscarinic acetylcholine receptor. For this purpose a three-dimensional
structure of the receptor at atomic resolution was built by homology modeling, using the crystallographic structure of bovine
rhodopsin as a template. Then, the antagonist N-methylscopolamine was docked in the model and subsequently embedded in a
lipid bilayer for its reﬁnement using molecular dynamics simulations. Two diﬀerent lipid bilayer compositions were studied: one
component palmitoyl-oleyl phosphatidylcholine (POPC) and two-component palmitoyl-oleyl phosphatidylcholine/palmitoyl-
oleyl phosphatidylserine (POPC-POPS). Analysis of the results suggested that residues F222 and T235 may contribute to the
ligand-receptor recognition. Accordingly, alanine mutants at positions 222 and 235 were constructed, expressed, and their binding
properties determined. The results conﬁrmed the role of these residues in modulating the binding aﬃnity of the ligand.
1.Introduction
Muscarinic acetylcholine receptors (mAchRs) are integral
membrane proteins that belong to the rhodopsin family of
G-protein-coupled receptors (GPCRs). These proteins play a
pivotalroleintheregulationofmanyphysiologicalfunctions
bothinthecentralandintheperipheralnervous systems[1].
Like other GPCRs, these proteins exhibit a basal activity that
is increased by the action of its natural agonist acetylcholine.
In the central nervous system, mAChRs are known to
regulate motor control, temperature homeostasis and are
involved in the process of memory and learning whereas,
in the peripheral system, they induce cardiovascular activity,
smooth muscle contraction, gland secretion, regulation of
cardiac activity, decrease blood pressure, and meiosis. The
physiological actions the natural agonist acetylcholine are
mediated by at least ﬁve subtypes of receptors known as M1-
M5 that exhibit high sequence identity across mammalian
species and exhibit diﬀerent tissue distribution [2, 3].
Binding of agonists and competitive antagonists to
GPCRs occurs at the orthosteric site, a hydrophobic pocket
located at the extracellular side of the helix bundle that
is highly conserved among the members of a subfamily
[4]. However, the binding of diﬀusing ligands to the
orthosteric site may be modulated by residues located at the
extracellular loops that ﬂank the entrance [5]. Interestingly,
while residues deﬁning the orthosteric binding site are well
conserved within the diﬀerent GPCR subfamilies, those
of the extracellular loops are remarkably diverse within a
subfamily, providing a good possibility to design selective
allosteric antagonist [6]. Although a wealth of information
about these receptors has been accumulated in the past,
there are still many questions open. Issues like the eﬀect
of the same mutation on the function of diﬀerent mAchRs
subtypes or the actual mapping of the binding site, as well as
the mechanism of activation, are poorly understood [7]. A
deeper understanding of the structure-activity relationships
of the diﬀerent subtypes will help designing new selective2 Journal of Biomedicine and Biotechnology
ligands with various pharmacological proﬁles that may be
useful for therapeutic intervention. In this sense, due to the
scarcity of crystallographic structures available, molecular
modeling methods can provide a deeper insight into the
ﬂexibility and the role that extracellular loops may play in
ligand recognition [8].
In the present work, we focus on the human M3
muscarinic acetylcholine receptor (M3R), which is involved
in modulation of neurotransmitter release, temperature
homeostasis, and food intake in the central nervous system,
as well as in the induction of smooth muscle contraction,
gland secretion, indirect relaxation of vascular smooth mus-
cle in the peripheral nervous system [1]. M3R is arranged
in the distinctive seven-transmembrane (TM) helix bundle
architecture like all GPCRs, with its N-terminus located
on the extracellular side of the plasma membrane and
the C-terminal tail in the cytoplasmic side. Helices are
connectedbyintracellularandextracellularloopsofdiﬀerent
lengthsexhibitingpreservedfeaturesoftherhodopsinfamily,
like the two highly conserved cysteine residues C221 and
C141, responsible for a disulﬁde bond between the second
extracellular loop (ECL2) and the TM3 helix [9].
We undertook a combined approach involving computa-
tionalandsite-directedmutagenesisstudiestofurtherdissect
M3R-ligand interactions with the aim of getting a deeper
insight into speciﬁc structural features that can modulate the
binding of the competitive antagonist N-methylscopolamine
(NMS) to the orthosteric site of the receptor. For this
purpose, we constructed an atomistic model of the M3R
that was further reﬁned using extended molecular dynamics
(MD) simulations of the protein embedded in a lipid
bilayer. The analysis of the MD trajectories provides a better
understanding of the structural features that characterize
the ligand-receptor interaction at the orthosteric pocket, the
dynamics of the extracellular loops, as well as its putative
involvement in ligand binding [10].
Present modeling studies suggest that residues F222
located in the ECL2 and T235 located at the edge of TM5
participate in the recognition of NMS. The former had
already been shown to be important for the binding of
allosteric modulators [11] but has not yet been shown to
modulate the binding of ligands to the orthosteric site. On
the other hand, the latter had already shown to be important
in conferring biding speciﬁcity to the physiological ligand
acetylcholine [12, 13]. Accordingly, in order to demonstrate
the prediction capabilities of the model, we designed and
expressed mutants F222A and T235A. Moreover, in order to
have a reference, other residues of the ECL2 not expected
to modulate the binding of NMS to M3 according to the
atomistic model but playing key roles in the binding of
allosteric modulators such as gallamine and alcuronium
in the M2 receptor [14] were also investigated. Thus, the
following mutants Y209F, K213V, and E228N were also
constructed and expressed.
Saturation binding assays were performed to determine
the aﬃnity of [3H]-NMS for these mutants. Dissociation
assays on the mutants were also performed in order to get
insight about the kinetics of the binding process. These
results suggest that residues F222 and T235 modulate the
binding of NMS [15] that show a slight decrease of its bind-
ing aﬃnity in contrast with the other mutants constructed
and tested.
2.MaterialsandMethods
2.1. Theoretical Methods
2.1.1. Construction of a M3 Receptor Model. A model of the
M3 receptor was constructed by homology modeling using
thecrystalstructureofbovinerhodopsinasatemplate(entry
1GZM of the Protein Data Bank) [16] by means of the
Modeller software [17] .T h eN - t e r m i n u sa sw e l la sal o n g
stretch of the C-terminus was not included in the model,
due to the low sequence identity exhibited between the two
sequences and that it does not presumably inﬂuence the
model for the purpose of the present work. Residues 264–
479, located in the third intracellular loop (ICL3), were
also removed and substituted by stretch of alanine residues
resulting into a shorter loop with the same length as that
found in rhodopsin. The model includes the full remaining
intradiscal and cytoplasmic loops, the conserved disulphide
bridge between the cysteine residues located in TM3 and
ECL2 (involving C141 and C221). All amino acids were
modeled in the protonation state; they would have as free
amino acids in water at pH 7 yielding a net charge of +17.
This net charge is later compensated in the simulation box
by adjusting the balance between sodium and chloride ions
to give an electroneutral system, as described in detail later.
Fifty diﬀerent models were generated following this
procedure. These were subsequently ranked ordered using
a scoring function based on structural compactness and
embedded in Modeller [17]. Structures were processed by
Procheck in order to assess the stereochemical quality of the
models generated [18]. The structure ﬁnally selected exhibits
the highest score with the minimum number of residues out
of the preferred regions of the Ramachandran plot.
Although the constructed model provides a reasonable
ﬁrst approximation of the receptor, it still exhibits some
limitations for its use in drug discovery [19]. First, con-
sideration of the rearrangement due to the bound ligand
and, second, the eﬀect of the lipid bilayer on the protein
structure are disregarded in the model constructed using a
crystal structure. These two eﬀects can be accounted for in
the model by means of molecular dynamics simulations.
2.1.2. MD Simulations. In order to understand the struc-
tural features of M3R, four 50ns molecular dynamics
simulations with the receptor embedded in a lipid bilayer
were carried out. Speciﬁcally, four trajectories were run:
with and without the antagonist NMS bound into the
orthosteric binding pocket and using two diﬀerent bilayer
compositions: a one-component palmitoyl-oleyl phos-
phatidylcholine (POPC) and a two-component palmitoyl-
oleyl phosphatidylcholine/palmitoyl-oleyl phosphatidylser-
ine (POPC/POPS), where POPS lipids were added at the
cytoplasmic surface of the M3R at a POPC/POPS 10:1 ratio.
The former bilayer was considered in the present paper
because it has been widely used in MD simulations; itsJournal of Biomedicine and Biotechnology 3
Figure 1: Snapshot of the system showing a ribbon representation
of the M3 receptor with N-methylscopolamine bound into the
orthosteric binding pocket, surrounded by POPC lipids. Waters
have been removed for clarity.
available force ﬁeld parameters are known to be carefully
calibrated and it is a good representative of the membrane
composition together with the fact that its gel/liquid-
crystalline phase transition is above the temperature of
the simulation (300K). Selection of the latter—a two-
componentbilayer—wasdoneinordertoinvestigatetherole
oftheinclusionofanioniclipidstoneutralizethenetpositive
charge located in the cytoplasmic region of the M3 receptor.
The M3R was placed in the center of an equilibrated
POPC box of dimensions 8.5 × 8.5 × 10nm (XYZ)
containing 256 molecules, a thick layer of water molecules
on each side of the bilayer, and NaCl ions at physiological
concentration of 0.2M taken from a previous study [20].
Overlapping molecules were removed following the proce-
dure described previously [20], in which all water molecules,
with oxygen atoms closer than 0.40nm to a nonhydrogen
atom of the protein, as well as all lipid molecules with at
least one atom closer than 0.25nm to a nonhydrogen atom
of the protein, were removed. This resulted in ﬁnal system
containing 189 lipids and ca. 14 600 water molecules. For
convenience, the system is organized in such a way that
the bilayer plane was oriented on the XY plane. For the
construction of the POPC/POPS box, the 10% of the POPC
molecules exhibiting the largest electrostatic potential were
replaced by POPS molecules. For those simulations with N-
methylscopolamine (NMS) bound into the orthosteric site,
theligandwasmanuallydocked, using information provided
by site-directed mutagenesis on relevant residues involved
in the binding [21]. Figure 1 shows the system showing a
cartoon of the M3 receptor with NMS bound, surrounded
by POPC molecules. Water molecules have been removed for
clarity.
Calculations were carried out by means of the GRO-
MACS 3.3.2 package [22] using periodic boundary condi-
tions. The all-atom OPLS force ﬁeld [23]w a su s e df o ra l l
the molecules of the system except for the lipids, for which
a speciﬁc parameterization was used [24]. This combination
has been previously employed [20]. Systems were subjected
to periodic boundary conditions in the three-coordinate
directions. Calculations were done at 300K using separate
thermostats for the protein, water, ions, and lipid molecules.
Thetimeconstantforthethermostatswassetto0.1ps,except
for water, for which a value of 0.01 was used. Equations of
motion were integrated using the leapfrog algorithm using a
time step of 2ps.
For equilibration, the system was subjected to 0.5ns MD
simulation to allow for the removal of voids present between
the protein and the lipid or water molecules. The simulation
was performed with the atomic coordinates of the protein
restrained to their crystallographic positions and allowing
the three periodic box dimensions to change size according
to a pressure of 0.1MPa in each coordinate direction [20].
Next,therestrainswerereleasedandthefourMDtrajectories
containing rhodopsin were computed up to 20ns each. As
a reference, eight additional simulations were performed
without protein and either with or without ions lasting
20ns each. For all simulations, coordinates were collected
every 10ps and were stored for further analysis. In all cases,
the ﬁrst 10ns were considered as equilibration period, and
therefore they are not included in the analysis. All the bonds
in the protein and lipid molecules were kept frozen using
the LINCS algorithm. Electrostatic interactions were treated
using the particle mesh Ewald summation procedure [25]
and nonbonded interactions were computed using a cutoﬀ
of 1.0nm.
3. Construction, Expression,andBinding
Assaysfor MutantM3R
3.1. Materials and Mutant Construction. 1-[N-methyl-3H]
scopolamine methyl chloride ([3H]-NMS; 84Ci/mmol)
was purchased from Perkin Elmer. Oligonucleotides were
designed and obtained from Sigma Aldrich (for the sequence
of the primers, see Figure 1(S) of Supplementary Materials
available online at doi:10.1155/2012/789741). The Quick
Change kit was from Stratagene (La Jolla, CA, USA).
Atropine was purchased from Sigma Aldrich.
Residues F222 and T235 of the human M3R were
mutated to alanine using the Quick Change method. Mutant
receptors, cloned into the pCD expression vector and con-
ﬁrmed by dideoxy sequencing, were transiently expressed in
COS-7 cells by electroporation (Bio-Rad Gene Pulser, 15μg
of DNA, 260V, 960μF). In the case of the T235A mutant, its
expression levels were improved by treatment of the cultured
cells with atropine (10−6 M) for 48h, before washing and
harvestingformembranepreparation.Theabilityofatropine
to act as a “pharmacological chaperone” has been described
previously [26]. After transfection, media was removed and
cellswerewashedtwicewithphosphatebuﬀeredsaline(PBS)
(in the case of mutant T235A, four additional washes were
needed to remove atropine), then harvesting buﬀer (20mM
Hepes, 10mM EDTA) was added to the ﬂasks. The cells were
incubated for about 10min and then scraped from the ﬂask.
The cells were pelleted and homogenized in a glass pestle
(×20 plunges on ice). This homogenate was transferred4 Journal of Biomedicine and Biotechnology
to JA-17 tubes and centrifuged at 17,000rpm at 4◦Cf o r
30 minutes. The pellet was resuspended in storage buﬀer
(20mM Hepes, 0.1mM EDTA). The cells were homogenized
on ice using a Polytron homogenizer setting 12,2 × 15s, the
membranes resuspended, snap frozen, and stored at −80◦C.
Protein concentration was determined using the Bradford
assay [27].
3.2. Radioactive Ligand Assays. [3H]-NMS saturation bind-
ing assays were performed by binding [3H] NMS (0.01–
3nM) to membrane preparations (10μg/mL of membrane
protein). Binding was measured at 30◦Ci nab u ﬀer con-
taining 20mM Hepes, 100mM NaCl, and 1mM MgCl2,
pH 7.5, using an assay volume of 1mL and an incubation
time of 2.5h. Nonspeciﬁc binding was determined with
1μM atropine. Assays were performed in quadruplicate. The
binding reaction was terminated by rapid ﬁltration on a
Brandel cell harvester (Brandel Model M-245, Serial 9219).
Dissociation kinetic assays were carried out to investigate
the time course of [3H]-NMS dissociation from the receptor.
COS7 cell membranes expressing the M3R (10μg/mL) were
equilibrated with 0.2nM [3H]-NMS in 1-mL total volume of
buﬀer containing 20mM Hepes, 100mM NaCl, and 1mM
MgCl2, pH 7.5 for 60min at 30◦C. Atropine (10μM) was
added at various time points to prevent radioligand re-
association to the mAchRs. Data analysis was carried out
b ym e a n so fG r a p hP a dP r i s m3 . 0( G r a p hP a dS o f t w a r e ,
San Diego, CA, USA). Saturation binding data were ﬁt
with hyperbolae (one-site binding); Bmax and Kd values
were derived from these curves. Dissociation kinetic data
were normalized and ﬁt to for a monoexponential decay
curves. Experiments were repeated 4 times. Log aﬃnities
were tabulated as mean ± SEM. Statistical comparison of
aﬃnity and dissociation rate constants for mutants and
WT M3R controls were carried out by one-way analysis of
variance followed by Dunnett’s post hoc test.
4. Results andDiscussion
As described in the Materials and Methods section, we used
r h o d o p s i na st e m p l a t e[ 28] for the generation of a starting
structureoftheM3Rbyhomologymodeling.Comparisonof
the transmembrane helices yields a 21.7% sequence identity
and a 42.9% sequence homology. Obviously, any of the
available crystal structures could have also been used for
this purpose, being the choice of a template to construct the
initial atomistic modelofa GPCRmatterofdebateinthesci-
entiﬁc community [29, 30]. Since for several years rhodopsin
was the only high-resolution GPCR structure available, most
of the homology modeling made use of it as template [31].
The recently published squid rhodopsin structure [32]a n d
a few ligand-activated structures the human β2adrenergic
receptor (β2AR) [33, 34], the avian β1adrenergic receptor
(β1AR) [35], the human A2A adenosine [36], and more
recently the crystal structure of the CXCR4 chemokine
[37] and the dopamine receptor [38] have brought the
opportunity to increase the repertoire of templates that can
be used for modeling purposes, opening the question of
which is the most suitable structure to be used. Indeed,
although the overall structure of the six proteins is similar,
therearenotablediﬀerences,mostlyintheextracellularloops
and in the ligand-binding region [39, 40]. For example, in
contrast to the other structures, the human β2adrenergic
receptor as well as of the avian β1adrenergic receptors exhibit
an alpha helix in the second extracellular loop. Similarly,
TM5 and TM6 in squid rhodopsin are more extended than
in the other receptors, or the inverse agonist in rhodopsin is
more deeply inserted inside the hydrophobic TM domain of
the protein. One of the conserved structural features, the so-
called ionic lock, is weaker in the case of the β1AR, β2AR and
A2A adenosine receptors than in the case of rhodopsin and
involves the ICL2. This latter diﬀerence may be responsible
for the higher basal activity and structural instability of these
receptors and may contribute to the challenges in obtaining
diﬀraction crystals of nonrhodopsin GPCRs [34].
However, there are still inconclusive results about the
choiceofatemplate.Thus,atthecommunity-wideassessment
of GPCR structure modeling hold in 2008 [41]a i m e da t
understanding of the performanceof GPCR homology mod-
eling, 206 models of the A2A adenosine receptor submitted
and assessed for their accuracy prior the release of the solved
crystal structure. These models were basically assessed by the
accuracy of the ligand-binding mode. The results show that
among the best models there are some that were constructed
using the structures of the β-adrenergic receptors and some
using rhodopsin. On the other hand, in a recent report
an accurate model of the transmembrane region of the
β2-adrenergic receptor was reported using rhodopsin as
template [42].
Two recently studies address the problem of template
selection for GPCR homology modeling [29, 30]. The two
studies conclude that the selection of the template should
not exclusively be based on sequence identity but on an a
priori assessment of the expected structural features of the
receptor wished to model and that more high-resolution
structures are still required. Moreover, the latter study
concludes that the best template needs to be considered
case by case, recommending the use of chimeras constructed
by selecting special features from the diﬀerent receptors
available. Unfortunately, the six crystallographic structures
available nowadays do not cover all the structural diversity
necessary to have adequate templates to model a speciﬁc
GPCRoftherhodopsinfamilyleavingthequestionstillopen.
5. MD Simulations
Deviations from the initial 7TM homology-based structure
were monitored through the time evolution of the root-
mean-square deviation (rmsd) of the α-carbon atoms as
displayed in Figure 2(a). Smaller deviations are observed
when the protein is embedded in the two-component lipid
bilayer (POPS-POPC) than when the protein is embedded
in the one-lipid environment (POPC) (Figure 2(a)). This
behavior is probably due to the presence of the anionic lipid
(POPS) in the cytoplasmic area of the receptor, neutralizing
the cluster of positive charges located in that region, andJournal of Biomedicine and Biotechnology 5
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Figure 2: (a) Time evolution of the root mean square deviation
(RMSD) of the of the α-carbon atoms of the protein along the
diﬀerent simulations. (b) Average root mean square deviation
(rmsd) of the Cα atoms of each residues of the protein through the
last 25ns of each simulations computed from an average of the last
25ns.
it is consistent with the experimental ﬁnding that this part
of the protein is diﬃcult to crystallize due to its ﬂexibility,
as previously found in MD simulations of bovine rhodopsin
[43]. The time evolution of the RMSD also permits to assess
the inﬂuence of the ligand on the protein structure. The evo-
lution of the α-carbon rmsd shows that the trajectories with
the ligand bound display lower deviations in comparison to
those simulations of the protein alone.
Deviations per residue were also computed for a better
characterization of the contribution of each segment to
the overall rmsd. Figure 2(b) shows the rmsd per residue,
highlighting the lower values found in the TM regions,
compared to the connecting loops. Speciﬁcally, the larger
deviations correspond to residues on the ICL2 and ICL3
of the protein (deviations larger than 1nm), whereas the
smaller ones correspond to the residues located in the TM
region of the protein (about 0.25nm). This diﬀerential
behavior can be correlated with the fact that receptor/G-
protein coupling occurs through the intracellular loops in all
mAChRs [44]. Furthermore, the structures embedded into
the two-component lipid bilayer (POPS/POPC) exhibit, in
general, smaller deviations as compared to those embedded
into one-component lipid bilayer with exceptions such as
residues in the intracellular loop ICL1 (135–140), in ICL2
(225–233), and residues in the ICL3 (520–535).
The root mean square ﬂuctuations (RMSF) of the α-
carbon atoms, taken as reference the average structure
computed from the last 25ns were also calculated for the
four trajectories. The largest ﬂuctuations are located on
the second and third intracellular loops as anticipated in
the rmsd calculations (for residue rmsf see Figure 2(S) of
Supplementary Materials). Fluctuations were relatively small
due to the restrictions imposed by the lipid bilayer, except
on the non-TM regions. In the case of TM4, TM5 and
TM6 show an overall larger ﬂuctuation in comparison to the
other TM helices. These results agree with the fact that some
residues within TM3-TM7 participate in the binding of the
antagonist ligand NMS [26, 45, 46].
Dihedral angles were also computed using four consecu-
tive α-carbons for the four MD simulations and disregarding
the ﬁrst 12ns (Table 1), in order to identify speciﬁc confor-
mations adopted by the extracellular loops when the NMS
antagonistisboundandintheligand-freereceptor.Theanal-
ysis of the M3-NMS-POPC MD trajectory shows that ECL1
adopts three diﬀerent conformations, whereas it adopts only
oneconformationintheotherthreesimulations.Incontrast,
ECL3 adopts only one conformation in the four MD trajec-
tories. On the other hand, the time evolution of the dihedral
angles deﬁned using four consecutive Cα of ECL2 shows that
it attains two diﬀerent conformations along the trajectories
M3R-NMS-POPC and M3R-NMS-POPC/POPS, whereas in
the M3-NMS-free POPC/POPS simulation exhibits three
diﬀerent conformations.
This observation agrees with the putative contribution
of ligands to generate microdomains on the extracellular
loops that are important for the conformational changes
that accompany receptor activation [47, 48]. Interestingly,
we can also see that most notable changes in the variation
of the dihedral angle average occur in the preceding part
of the residues 218–221; therefore it seems that residues
near the C221, the one that forms a disulphide bond with
C141, play an important role in the conformation of this
second extracellular loop. Figure 3 shows the superposition
of two snapshots at diﬀerent times taken from the POPC
simulation, where it can clearly be seen the distinctive
features the conformation adopted by the ECL2 before the
ﬁrst 20ns and after 20ns of the simulation.
I no r d e rt os t u d yd i ﬀerent speciﬁc structural features,
we focused on residue-residue hydrogen-bonding inter-
actions, and lipid-protein interactions. For the protein-
protein intramolecular interactions, we focused on hydrogen
bond formation and breaking between pairs of residues6 Journal of Biomedicine and Biotechnology
Table 1: Values of the dihedral angles of four consecutive Cα alpha carbons corresponding to the three extracellular loops: (a) ECL1, (b)
ECL2, and (c) ECL3 of M3R for the four MD trajectories computed in the present work.
(a) ECL1
Dihedral angles/degrees
129–132 130–133 131–134 132–135 133–136 134–137 135–138 136–139
M3–NMS-POPC
(12–26ns) 32 −141 65 −108 49 52 −82 −59
(27–39ns) 75 −75 87 −108 119 38 −123 −45
(39–50ns) −20 −125 13 −108 119 38 −123 −45
M3–NMS-POPC/POPS
(12–50ns) 32 −150 89 −132 140 60 −100 −45
M3 free POPC
(12–50ns) −97 184 −200 85 59 −137 −43 96
M3 free POPC/POPS
(12–50ns) −165 46 −187 73 65 58 −80 4
(b) ECL2
Dihedral angles/degrees
208–211 209–212 210–213 211–214 212–215 213–216 214–217 215–218 216–219 217–220 218–221
M3-NMS-POPC
(12–20ns) 142 −66 52 −38 117 24 −95 −104 −142 −95 32
(21–50ns) 142 −66 52 −38 112 −12 151 −120 −109 14 32
M3 NMS POPC/POPS
(12–25ns) 79 −86 0 −37 75 94 −40 −97 −90 −62 5
(25–50ns) 79 −86 0 −37 53 55 66 −127 −88 26 76
M3 Free POPC
(12–50ns) 90 3 75 −50 60 115 35 −140 −150 −75 74
M3 free POPC/POPS
(12–18ns) 95 −9 53 42 59 112 36 −152 −140 −79 70
(18–35ns) 112 −9 102 118 88 96 62 −161 −140 −79 70
(35–50ns) 122 36 37 −82 98 118 76 −161 −138 −79 70
(b) ECL2
Dihedral angles/degrees
219–222 220–223 221–224 222–225 223–226 224–227 225–228 226–229 227–230 228–231 229–232 230–233
M3 NMS POPC
(12–50ns) −110 114 −63 126 −145 −141 20 85 146 81 99 76
M3 NMS POPC/POPS
(12–50ns) −148 72 −100 −25 −150 105 −25 61 −147 65 74 77
M3 free POPC
(12–50ns) −86 88 −79 −152 −139 126 41 12 −159 78 92 75
M3 free POPC/POPS
(12–50ns) −82 93 −90 −182 −136 123 20 107 −152 33 62 127
(c) ECL3
Dihedral angles/degrees
513–516 514–517 515–518 516–519 517–520 518–521 519–522 520–523
M3 NMS POPC
(12–50ns) 126 80 −120 53 90 175 −133 −98
M3 NMS POPC/POPS
(12–50ns) 125 80 −132 62 100 −140 −146 −109
M3 free POPC
(12–50ns) 132 45 −113 74 68 −162 −138 −104
M3 free POPC/POPS
(12–50ns) −22 191 130 21 −189 109 14 165Journal of Biomedicine and Biotechnology 7
C 221
C 141
TM III
TM V
TM IV
Figure 3: Superposition of two snapshots of the NMS POPC MD
trajectorywithNMSboundattheorthostericbindingsiteoftheM3
receptor. In blue a snapshot before 20ns and in pink after 20ns.
of the protein along the MD trajectory (Figure 4(a)). The
analysis was carried out by counting all possible atoms
involved in a hydrogen/charge interaction around one
residue at a time using a cutoﬀ of 0.4nm. Figure 7 lists
the interactions between residues and their persistence
along the MD trajectories. They are classiﬁed in charged-
charged, charged-noncharged and noncharged-noncharged.
Among the residues listed in Figure 7, those forming the
so-called ionic-lock between TM3 and TM6, in subscript
the Ballesteros-Weinstein numbering is used [49]: D1653.49,
R1663.50, Y1673.51 and E4866.30, R2535.60 and R1804.37 are
indicated. Electrostatic interactions at these positions are
known to be critical for restraining the receptor from
adopting a constitutively active GPCR [50, 51]. Some of
the interactions are only found in the two POPS/POPC
simulations: D142-K213, D165-R166, E259-R480, E220-
Y128, E220-Y530, and N548-T50. Other interactions can
only be found in the POPC simulations: E257-R253,
E486-R177, S121-Y534, T534-S121, T550-Q98, and T550-
T554. Furthermore, some of the interactions are found
in the simulations without ligand: D165-R184, E257-Y167,
N104-Y544, Y149-T235. Finally, some residues are only
found when the ligand is bound to the receptor: D165-
R180, E220-K523, D148-S152, N104-T101, and S537-S152
(Figure 7).
Ontheotherside,speciﬁcresidueshavebeenshowntobe
involved in protein-lipid interactions. These include charged
like K and R, neutral like N, Q, T, and S, and aromatic like
H, Y, and W [20]. Previous analysis of hydrogen bonding
among protein donors of bovine rhodopsin and lipid oxygen
atoms revealed the importance of these interactions for the
anchoring of the protein to the membrane. In rhodopsin,
residues R2526.35,Y 9 6 2.63, Y2746.57, H1524.41 and T1083.23,
and to a lower extent K661.61,R 6 9 1.64, Y1353.50, and W351.30
are found to participate in hydrogen bond linkages with
TM III
TM V
TM IV TM VI
R 253
Y 167 R 166
D 165
R 180
E 486
(a)
T 127
K 523
W 66
S 519
W 252
K 94
Y 105
Y 167
255
K 256
R 253
R 184
K 100
(b)
Figure 4: (a) Residues involved in the electrostatic lock between
TM3 and TM6 helices in M3R. (b) Residues of M3R involved in
hydrogen bonding with lipid oxygens. In bold are those residues
have been also identiﬁed in a similar study in Rhodopsin (see text).
W661.30,K 9 4 1.58, K1001.64, T1272.63, Y1673.51, R1844.41, W2526.33,
R2536.34, Y2556.36, K256 6.37, S5196.64, and K5236.68.
lipid molecules, and, therefore, they can be considered to
be putative hooks of the protein to the bilayer [20]. In
thiswork,speciﬁchydrophiliclipid-proteininteractionshave
been analyzed along the diﬀerent trajectories using the
criteria ofanyoftheresidue atomsofthe receptorwaswithin
ac u t o ﬀ of 0.4nm of a lipid oxygen. Following this approach,
we identiﬁed common interactions for the four trajectories
studied (Figure 4(b)). Most of the lipid-protein interactions
are detected at the cytoplasmic half of the receptor, similarly
to what is found in the case of rhodopsin. Moreover, some
of the residues in M3R, W661.30, K1001.64, T1272.63, Y1673.51,
and R1844.41, correspond to homologous residues in the
rhodopsinsequencethatconfersthevisualphotoreceptorthe
property of anchoring the protein onto the lipid bilayer [20].8 Journal of Biomedicine and Biotechnology
I 223
F 222
Y 149 D 148
Y 534
C 533
S 152 N 153 T 235
N 508
A 239
W 504 A 236
L 512
Figure 5: Binding pocket of the M3R: D1483.32, S1523.36, N1533.37,
F222(ECL2), I223(ECL2), T2355.42, A2365.43, A2395.46, W5046.48,
N5086.52, V5116.55, L5126.56, C5337.40, and Y5347.41.
Another point of interest arises from the comparison of
the interactions using the two diﬀerent bilayers. In this case,
the location of POPS lipids in the cytoplasmic vicinity of
the receptor would provide a larger number of these lipid-
protein interactions due to the fact that carboxylate groups
of POPS lipids can interact with positively charged residues
such as K260, R261, K263, R480, K487, and K488 located at
ICL3 of the receptor.
6. The Orthosteric BindingPocket of M3R
NMS was docked onto the binding pocket of M3R taking
into account the residues known to aﬀect its binding from
site-directed mutagenesis studies, speciﬁcally D3.32 known
to interact with the ligand quaternary nitrogen [52], N6.52
putativelyinvolvedinapolarinteractionwiththeligand[53–
55], and the homologous hydrophobic residues implicated
in the binding of NMS at the M1 muscarinic receptor
[56]. Once docked, the complex was energy minimized and
the MD simulation started. This process was done for the
two diﬀerent bilayer compositions studied in the present
work, POPC and a 10:1 POPC/POPS mixture. In order
to understand the stereochemical features of the binding
pocket, we monitored all the residues within a cutoﬀ of
0.35nm of any of the atoms of the ligand along the MD tra-
jectories.ResiduesinvolvedinthebindingofNMSareshown
in Figure 5. Simultaneously, we monitored the diﬀerent
conformations the ligand attained during the simulations.
The analysis reveals that the ligand actually adopts diﬀerent
conformations along the trajectories; however, all of them
conserve the interaction between the quaternary nitrogen of
NMSwiththesidechainofD1483.32 andthehydroxylmoiety
with N5086.52 (for deﬁnition of NMS dihedral angles and
theirvaluesalongtheMDtrajectoryseeFigures3(S)and4(S)
of the Supplementary Material). Two diﬀerent representative
conformations of the ligand along the MD trajectories are
depicted in Figure 6.
A 239
Y 149
I 223
W 504
D 148
F 222
(a)
A 239
W 504
N 153
Y 149
F 222
D 148
S 152
(b)
Figure 6: Diﬀerent conformations that ligand exhibits in the
two diﬀerent simulations: POPC and POPC/POPS simulation. (a)
Superposition of two snapshots of the POPC MD simulation at 15
and 40ns. (b) Superposition of two snapshots of the POPC/POPS
simulation at 25 and 45ns.
In a detailed analysis of hydrogen bonding interactions
between diﬀerent residues of the protein (those within a
cut-oﬀ of 0.35nm) and atoms of NMS, we computed the
average angle formation of each of the interactions along the
dynamics, and we found that residues N5086.52, W5046.48,
F222, and T235 of M3R participate in hydrogen bond
formation (angle between 120◦–180◦)w i t hs p e c i ﬁ ca t o m s
of the antagonist ligand NMS in the MD simulations. In
agreement with previously published results literature [57],
N6.52 is considered to be important for the binding of some
muscarinic antagonists [53], and also W6.48 has also been
shown to be important for the binding of NMS [45, 51].
We have constructed, expressed, and characterized the
alanine mutants of F222 and T235 and studied them by
means of saturation binding assays in order to determine
the aﬃnity of NMS for these mutants. Dissociation binding
assays have also been performed to study the release of NMS
as a function of time from the M3R, in 20mM Hepes buﬀer.
Infact,thecorrespondinghomologouspositionshaveshown
to modulate binding of NMS to the M1 receptor [47, 58].
Thus, mutant Y177 (the corresponding position of F222)
reduced the aﬃnity of NMS about 2.2-fold in comparisonJournal of Biomedicine and Biotechnology 9
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Figure 7:Residue-residueinteractionsidentiﬁedinthefourMDtrajectoriestogetherwiththeirresidencetimes.A:ligand-freeM3trajectory
in POPC; B: ligand-free M3 trajectory in POPC/POPS; C: M3-NMS complex in POPC; D: M3-NMS complex in POPC/POPS. Color scale:
black, the interaction in present during the whole trajectory; grey, the interaction is present more than 50% of the trajectory; light grey, the
interaction is present less than 50% of the trajectory. Residues in bold are those found in rhodopsin (Cordomi and Perez, 2007). Residues in
italics are tentatively involved in the ion lock of M3R.
Table 2: Determination of the Log aﬃnity and Bmax values of M3
WT receptor and mutant receptors: F222A and T235A. The aﬃnity
constants and ranges of Bmax values of 3H NMS at M3 WT and
mutant receptors F222A and T235A expressed in COS-7 cells are
shown as the log values ± standard error.
Receptors Bmax fmol/mg prot LogKd NMS n
WT M3 1900–3400 9.55 ±0.044 4
F222A 1213–1780 9.30 ±0.036 4
T235A 1734–2460 9.14 ±0.024 4
to WT M1 [47]. Furthermore, the mutant T1925.42 (the
corresponding position of T235) showed a reduction of the
aﬃnity of NMS about 1.69 compared to the WT M1 [58].
7. ExpressionandExperimental
Characterizationof WT M3R and Mutants
The eﬀect of the mutations studied on the expression of
mAChR was measured by saturation binding assays using
[3H] NMS (for representative saturation binding curves
see Figure 5(S) of the Supplementary Materials). Mutant
F222A showed about 55% of expression level in comparison
to the WT M3R. In the case of the T235A mutant, it
showed lower expression levels that were improved after
atropine treatment. Alanine substitution of residues F222
and T235 somehow resulted in reduced aﬃnities for NMS
when compared to WT M3R. Mutant F222A decreased the
aﬃnity for NMS by 1.7-fold and mutant T235A by 2.6
fold with regard to WT M3R (Table 2). However, Y209F,
K213V, and E228N mutants assayed in parallel did not
show any signiﬁcant diﬀerence with regard to WT M3R
(data not shown) which is consistent with the proposed role
for these position in allosteric—but not in orthosteric—
ligand binding [14]. The measurement of dissociation time
courses was carried out in order to provide information
about the transition from the conformation of the receptor
bound to the radioligand and the free state of the receptor.
[3H] NMS dissociated from the WT M3 receptor with a
monoexponential time course time course corresponding to
a half-time of 10min under this condition (20mM Hepes
buﬀer, 30◦C) which is in good agreement with previously
published values [59]. Dissociation rates for the mutants10 Journal of Biomedicine and Biotechnology
F222A and T235A were not signiﬁcantly diﬀerent from the
WT M3 receptor (data not shown). The eﬀect observed
in the binding aﬃnities, together with the lack of eﬀect
in the dissociation analysis, suggests diﬀerent structural
environment requirements for the binding and dissociation
of the ligand to and from the receptor.
8. Conclusions
The present paper addresses the eﬀect of lipid composition
and the antagonist ligand on the structure of the human
M3R. The atomic resolution model of the M3R constructed
by homology modeling using the crystal structure of bovine
rhodopsin is compatible with experimental data from site
directedmutagenesisstudiesandrepresentstheinactiveform
of the receptor. This model was reﬁned by MD simulations
and the eﬀect of the ligand on the conformation of the
protein analyzed. Therefore, MD trajectories of diﬀerent
component lipid bilayers (POPC and the two-component
POPC/POPS lipid bilayer), and also with or without NMS
within the orthosteric binding site of M3R receptor, were
analyzed.
We could determine that POPS lipid molecules provide
additional stabilization to the protein structure of human
M3R, especially for ICL3 because charged residues localized
in this area of the receptor interact with the lipid oxygen
atoms of the POPS molecule. Furthermore, our lipid-
protein analysis suggests that some speciﬁc residues in the
GPCR family (positions 1.30, 1.64, 2.63, 3.51, and 4.41)
are responsible for anchoring the membrane protein onto
the lipid bilayer (e.g., rhodopsin and M3R), as previously
hypothesized [20, 60].
Our modeling identiﬁed many polar interactions that
could play a role as activation microswitches [61, 62]. This
includes also interactions associated to the “ionic lock”
located at the cytoplasmic ends of the third and sixth
transmembrane helices, respectively, (positions: 3.49, 3.50,
3.51, 6.30, and 6.34 in the GPCR family) play an important
role in the receptor activation mechanism [50, 63].
In agreement with previous molecular modeling and
mutagenesis for other muscarinic receptors (Avlani et al.,
2007) [5], we found that ECL2 has a requisite of ﬂexibility
promoting the binding of GPCR ligands despite of the
presence of the disulphide bridge between this loop and
TM3. As seen in our average dihedral angle calculations, this
loop showed more ﬂexibility in comparison to ECL1 and
ECL3. This loop ﬂuctuates in two diﬀerent conformations
(most notable changes occur in the residues preceding
C221—involved in the disulﬁde bridge—in the two MD
simulations in which the ligand NMS was inside the binding
pocket.
On the other hand, our experimental ligand binding
and dissociation results suggest that, although F222 and
T235 are not critical in the binding of NMS, these residues
may participate in the conformation of a optimal binding
pocket of NMS, where every small contribution in the
environment confers stability to the NMS-receptor complex.
Further studies, using other experimental conditions, will be
needed to determine the potential role of these residues in
binding of other ligands, for example, agonists or allosteric
modulators.
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